Chinese patent medicines for the treatment of the common cold: a systematic review of randomized clinical trials

Wei Chen, Bo Liu, Li-qiong Wang, Jun Ren, Jian-ping Liu, Wei Chen, Bo Liu, Li-qiong Wang, Jun Ren, Jian-ping Liu

Abstract

Background: Many Chinese patent medicines (CPMs) have been authorized by the Chinese State of Food and Drug Administration for the treatment of the common cold. A number of clinical trials have been conducted and published. However, there is no systematic review or meta-analysis on their efficacy and safety for the common cold to justify their clinical use.

Methods: We searched CENTRAL, MEDLINE, EMBASE, SinoMed, CNKI, VIP, China Important Conference Papers Database, China Dissertation Database, and online clinical trial registry websites for published and unpublished randomized clinical trials (RCTs) of CPMs for the common cold till 31 March 2013. Revman 5.2 software was used for data analysis with effect estimate presented as relative risk (RR) and mean difference (MD) with a 95% confidence interval (CI).

Results: A total of five RCTs were identified. All of the RCTs were of high risk of bias with flawed study design and poor methodological quality. All RCTs included children aged between 6 months to 14 years. Results of individual trials showed that Shuanghuanglian oral liquid (RR 4.00; 95% CI: 2.26 to 7.08), and Xiaoer Resuqing oral liquid (RR 1.43; 95% CI: 1.15 to 1.77) had higher cure rates compared with antivirus drugs. Most of the trials did not report adverse events, and the safety of CPMs was still uncertain.

Conclusions: Some CPMs showed a potential positive effect for the common cold on cure rate. However, due to the poor methodology quality and the defects in the clinical design of the included RCTs, such as the lack of placebo controlled trials, the inappropriate comparison intervention and outcome measurement, the confirmative conclusions on the beneficial effect of CPMs for the common cold could not be drawn.

Figures

Figure 1
Figure 1
Flow chart of included studies in this systematic review.
Figure 2
Figure 2
Risk of bias summary about each risk of bias item for each included study.
Figure 3
Figure 3
Forest plot of comparison of CPM with antivirus drugs on cure rate.

References

    1. Turner RB. The treatment of rhinovirus infections: progress and potential. Antivir Res. 2001;49:1–4. doi: 10.1016/S0166-3542(00)00135-2.
    1. Garibaldi RA. Epidemiology of community-acquired respiratory tract infections in adults. Incidence, etiology, and impact. Am J Med. 1985;78:32–37. doi: 10.1016/0002-9343(85)90361-4.
    1. Simasek M, Blandino DA. Treatment of the common cold. Am Fam Physician. 2007;75:515–520.
    1. Arroll B. Common cold. Clin Evid (Online) 2011;16:2011.
    1. Kenealy T, Arroll B: Antibiotics for the common cold and acute purulent rhinitis.Cochrane Database Syst Rev 2013., (6): Art. No.: CD000247. doi: 10.1002/14651858.CD000247.pub3
    1. Kim SY, Chang YJ, Cho HM, Hwang YW, Moon YS: Non-steroidal anti-inflammatory drugs for the common cold.Cochrane Database Syst Rev 2013., (6): Art. No.: CD006362. doi:10.1002/14651858.CD006362.pub3
    1. Eccles R. Efficacy and safety of over-the-counter analgesics in the treatment of common cold and flu. J Clin Pharm Ther. 2006;31:309–319. doi: 10.1111/j.1365-2710.2006.00754.x.
    1. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Altman DG, Sterne JAC, Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) 2011.
    1. Lv GQ. Chaihu injection acupoint block in treating pediatric cold and fever. Inner Mongol J of Traditional Chinese Med. 2010;29:151–152.
    1. Di JH. Clinical observation of Ganmao Qingre granules in treating pediatric wind-cold type of common cold in 30 cases. Chin Pediatr Integr Traditional Western Med. 2012;4:277–278.
    1. Wang HR, Wang YF. Clincal observation of Shuanghuanglian oral liquid in treating children with upper respiratory tract infection. Qingdao Med J. 1997;29:40.
    1. Wu CF, Guan MC, Chi XW. Clinial observation of Xiaoer Baotaikang granules in treating children with upper respiratory tract infection. Strait Pharmaceut J. 2012;24:239–240.
    1. Li QF, Song M. Clinical observation of Xiaoer Resuqing oral liquid in treating pediatric cold and fever. Shandong Med J. 2007;47:24.
    1. Kjaergard LL, Villumsen J, Gluud C. Reported methodological quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med. 2001;135:982–989.
    1. Schulz KF, Chalmers I, Hayes R, Altman D. Empirical evidence of bias. JAMA. 1995;273:408–412. doi: 10.1001/jama.1995.03520290060030.
    1. Joint Formulary Committee . British National Formulary (BNF) 65. London: Pharmaceutical Press; 2014.
    1. Ribavirin, Drugs website [] (accessed 29 May 2014)
    1. Ribavirin, MedlinePlus website [] (accessed 29 May 2014)
    1. Chiou HE, Liu CL, Buttrey MJ, Kuo HP, Liu HW, Kuo HT, Lu YT. Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: experience in two medical centers. Chest. 2005;128:263–272. doi: 10.1378/chest.128.1.263.
    1. Zhang X, Wu T, Zhang J, Yan Q, Xie L, Liu GJ: Chinese medicinal herbs for the common cold.Cochrane Database Syst Rev 2007., (1): Art. No.: CD004782. doi: 10.1002/14651858.CD004782.pub2
    1. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trial. BMJ. 2010;340:c869. doi: 10.1136/bmj.c869.
Pre-publication history
    1. The pre-publication history for this paper can be accessed here:

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する